Q&A

Q&A: 7 Key Biosimilars Questions Answered

Source: Life Science Leader
Q&A: 7 Key Biosimilars Questions Answered

By Life Science Leader magazine.

In the July issue of Life Science Leader, Cliff Mintz wrote a global update on follow-on biologics in unregulated markets, the European Union, and the United States. With intense public debate around healthcare reform, and several biosimilars bills in Congress, many companies are no longer seeing biosimilars as a question of “if,” but rather “when.” In response, Life Science Leader sat down with Anita Marie O’Connor, Ph.D., senior director for biopharmaceuticals at MDS Pharma Services, a provider of drug discovery and early-stage development services, to discuss the challenges facing companies embarking on biosimilars.

Used with permission from Life Science Leader magazine.

VIEW THE Q&A!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Biosimilar Development? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: